Search results for "biologic"

Article USP Publishes Monoclonal Antibody Guidelines
Morris, PhD BioPharm International Volume 3, Issue 28 As FDA gears up towards approving biosimilar drugs in the United States, it is unquestionable that the role of biologics has rapidly expa…

Article FDA Approves First Biosimilar
To date, there are a total of five 351(k) applications that are publicly disclosed, including the one for Zarxio, said Leah Christl, associate director for therapeutic biologics and biosimilars in the…

Article Quality by design for biotechnology products—part 1
Although biologic and biotechnology products often present a higher level of complexity than small molecules in terms of manufacturing process or product structure, the concepts of QbD are the same as…

Article Sterilization Trends for Single-Use Consumables
Staying abreast of and managing trends in sterilization of SU consumables is therefore essential for biologics producers. Several sterilization process essentials Contamination poses a huge risk t…

Article Advances in Sterilization Technologies for Overcoming Viral-Vector Manufacturing Challenges
For most biologics, therefore, sterility must be assured by using aseptic processing techniques, which involve use of sterile raw materials, equipment, and processes under conditions that prevent micr…

Article A Diverse Landscape of Patent Issues Seen in the US, UK, and the EU
England (Taylor Wessing): Increasing patent litigation is being seen concerning biosimilar versions of biological products, most often monoclonal antibody treatments. The complexity and value of these…

Article Addressing the Complex Nature of Downstream Processing with QbD
The industry has been slowly adopting the QbD approach, but with the boom in the biopharma industry, how have these QbD principles fit into the complex nature of biologics? According to Gunnar Malmqui…

Article Nurturing Knowledge from Disparate Data Streams
  Bigger challenges for biologics Biologic drugs pose some additional challenges beyond those associated with chemical APIs. Small molecules have one structure and composition. Because biologi…

Article Advances in Engineering of Protein-Based APIs
Blincyto, a BiTE targeting CD3 and CD19, became the first bispecific biologic approved in the US market and demonstrates the impact bispecific molecules can have on treatment of disease, according to …

Article Scaling Up Novel Therapies
The key to making gene therapy accessible to patients will be better manufacturing processes, Peter Marks, director of FDA’s Center for Biologics Evaluation and Research, told attendees at the Galien …

Previous PageNext Page